TF2- Small Cell Lung Cancer Radio Immunotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lung cancer is currently the leading cause of cancer death in both men and women in Europe, with an estimated 250000 new cases diagnosed in 2005. The continued poor outcome of patients indicates that the current recommended regimens are falling short. In addition, many of the commonly used chemotherapy agents are associated with severe nonhematologic toxicities that are often cumulative and nonreversible and impair quality of life in this essentially palliative setting. Therefore, agents with novel mechanisms of action and superior safety profiles need to be investigated. More than 50% of lung cancer shows carcinoembryonic antigen (CEA) expression and anti-CEA radioimmunotherapy (RAIT) could be used. The investigators group showed that pretargeted RAIT (PRAIT) using bispecific antibody (bsMAb) can deliver a higher radiation dose to a tumor than a directly radiolabeled anti-CEA antibody, and shows improved anti-tumor efficacy. This clinical trial is designed to assess PRAIT using an entirely new recombinant anti-CEA bsMAb and a 177Lu-labeled peptide for the treatment of CEA-expressing small cell lung cancers (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

NCT01730612

HER2 Negative Breast Carcinoma Expressing CEA

COMPLETED PHASE1/PHASE2

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy

NCT05111197

Locally Advanced Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer

UNKNOWN PHASE3

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

NCT02463994

Non-small Cell Lung Cancer

COMPLETED EARLY_PHASE1

Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer

NCT02720614

Non-small Cell Lung Cancer

COMPLETED PHASE2

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

NCT03035890

Non Small Cell Lung Cancer Metastatic

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this open-label prospective optimization and phase I/II clinical trial is to examine the safety, optimal dose, targeting, dosimetry and efficacy of PRAIT using the humanized anti-CEA x anti-HSG bsMAb TF2 and the 177Lu-IMP-288 peptide pretargeted in patients with CEA-positive SCLC or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

This study has 2 parts: Study plan I (Optimization study) and Study plan II (Escalating activity phase I/II study).

The Study plan I is designed to optimize the pretargeting procedure using blood pharmacokinetics (Pk) and dosimetry in 9 patients receiving escalating doses of TF2 followed 2 to 4 days later by 1.1 GBq/m2 of 177Lu-IMP-288.

The study plan II is designed to determined MTD of 177Lu-IMP-288 using dosimetry and toxicity data in a phase I/II study performed in patients receiving optimal dose of TF2 bsMAb (determined in study plan I) followed 2 to 4 days by escalating activity of 177Lu-IMP-288.

A pre-therapy imaging study (using TF2 followed 2 to 4 days later by 185 MBq of 111In-IMP-288) is performed in the two study plans to qualify a patient for treatment with the subsequent therapy dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small Cell Lung Cancer CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antibody TF2

preciblage with an antibody

Intervention Type DRUG

IMP-288-Lutetium

Internal Radiation

Intervention Type RADIATION

IMP-288-Indium

Imaging

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Patients with histologic diagnosis of SCLC who are in partial response or who have failed at least two lines of standard radiation and/or chemotherapy. Outside formal contra-indication, patients must have received at least one prior platinum-based chemotherapy.

or

* Patients with histologic diagnosis of NSCLC (without activating mutation of EGFR gene) who have failed at least one line of chemotherapy (platinum in combination with a third generation drug or combination of 2 third generation drug +/-bevacizumab in case of predominance of non-squamous tumor)
* Age ≥ 18 years
* At least 4-weeks after the previous treatment and have recovered from previous radio- or chemotherapy
* Women of child-bearing potential must have a negative pregnancy test.
* Karnofsky performance status ≥ 60 or ECOG performance status 0-2Karnofsky
* Minimum life expectancy of 3 months
* Positive CEA on immunohistology or plasma CEA ≥ 10 ng/mL
* At least one measurable lesion by CT
* At least one abnormal focus by FDG-PET
* Imaging studies must be performed within 1-4 weeks before PRAIT study to document extent of disease
* Signed informed consent form.

Exclusion Criteria

* Pregnant or lactating woman. Women of child-bearing potential will be asked to practice adequate means of birth control for a minimum of 12 months after treatment.
* Male patient refusing effective contraception for a minimum of 12 months after treatment.
* Brain metastases but patients with brain metastases controlled after treatment by Surgery or radiotherapy since more than 4 weeks are eligibles for the study. An treatment by associated corticotherapy is authorized for these patients.
* Known HIV or hepatitis
* Any serious active disease or comorbid medical condition (according to the investigator's decision and information provided in the IDB)
* Severe disorders of hemostasis or anticoagulant treatment cure
* Extensive irradiation to more than 25% of their red marrow
* Bone marrow involvement to more than 25%
* External radiation to specific organs or areas at the maximum tolerated level
* EGFR gene mutation in tumor (only for NSCLC)
* Febrile aplasia during a previous chemotherapy
* Neutrophils \< 1.5 G/l
* Platelets \< 100 G/l
* Uncontrolled diabetes
* Poor renal function (creatinine level \> 2.5 maximum normal level)
* Poor hepatic function (total bilirubin level \> 30 mmol/l, transaminases \> 2.5 maximum normal level)
* Treatment with any investigational drug within 30 days before planned PRAIT and during the study
* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma,
* Presence of anti-antibody reactivity
* Known hypersensitivity to murine antibodies or proteins
* Adult patient unable to give informed consent because of intellectual impairment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No